<html lang="en" class="pb-page js" data-request-id="94d64be1069800ae-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d64be1069800ae-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/K8lBVpLN_ZryGJxQKHkCXx-qa3REN64E-J30Z12FPsAH94tb3cNpcXjttKfI0ki-YBD-d6PePMi5FufvKvh89Q=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d64be1069800ae-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.43122703712308985"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Cardiology|Genetics|Pediatrics">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Lipids|Genetics General|Cardiology General|Pediatrics General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2019910","title":"Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia","category":"Research","type":"Original Article","topics":"Lipids|Genetics General|Cardiology General|Pediatrics General","specialties":"Cardiology|Genetics|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-10-01T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Cardiology|Genetics|Pediatrics\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Lipids|Genetics General|Cardiology General|Pediatrics General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2019910","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Evolocumab in Pediatric Heterozygous FH","doi":"10.1056/NEJMdo005857","issueDate":"2020-10-01T00:00Z","age":"6Months-1990","isFree":"y","topics":"Lipids|Genetics General|Cardiology General|Pediatrics General","viewType":"Full","specialties":"Cardiology|Genetics|Pediatrics"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d64be1069800ae-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia"><meta name="dc.Creator" content="Raul D. Santos"><meta name="dc.Creator" content="Andrea Ruzza"><meta name="dc.Creator" content="G. Kees Hovingh"><meta name="dc.Creator" content="Albert Wiegman"><meta name="dc.Creator" content="François Mach"><meta name="dc.Creator" content="Christopher E. Kurtz"><meta name="dc.Creator" content="Andrew Hamer"><meta name="dc.Creator" content="Ian Bridges"><meta name="dc.Creator" content="Andrea Bartuli"><meta name="dc.Creator" content="Jean Bergeron"><meta name="dc.Creator" content="Tamás Szamosi"><meta name="dc.Creator" content="Saikat Santra"><meta name="dc.Creator" content="Claudia Stefanutti"><meta name="dc.Creator" content="Olivier S. Descamps"><meta name="dc.Creator" content="Susanne Greber-Platzer"><meta name="dc.Creator" content="Ilse Luirink"><meta name="dc.Creator" content="John J.P. Kastelein"><meta name="dc.Creator" content="Daniel Gaudet"><meta name="dc.Description" content="Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol lev..."><meta name="Description" content="Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol lev..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-10-01"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2019910"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202010013831407"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2027599"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2019910">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2019910">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2019910">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia | NEJM">
        <meta property="og:title" content="Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2019910">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ed8a5984-4314-4602-b625-3ba9ad4f18bd/nejmoa2019910_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ed8a5984-4314-4602-b625-3ba9ad4f18bd/nejmoa2019910_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Evolocumab, a fully human monoclonal antibody directed against proprotein convertase
subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein
(LDL) cholesterol lev...">
        <meta name="twitter:description" content="Evolocumab, a fully human monoclonal antibody directed against proprotein convertase
subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein
(LDL) cholesterol lev...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1433">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2019910">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2019910">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;issue:issue:doi\:10.1056/nejm_2020.383.issue-14;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;article:article:doi\:10.1056/NEJMoa2019910;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2019910" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2019910" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2019910" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2019910" class="inputDoi"><input type="hidden" value="R.D. Santos and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:1317-1327" class="inputCitation"><input type="hidden" value="08-29-2020" class="inputEPubDate"><input type="hidden" value="October 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d64be1069800ae-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Raul D.</span> <span property="familyName">Santos</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-9860-6582" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-9860-6582</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrea</span> <span property="familyName">Ruzza</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">G. Kees</span> <span property="familyName">Hovingh</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-8043-951X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-8043-951X</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Albert</span> <span property="familyName">Wiegman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">François</span> <span property="familyName">Mach</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher E.</span> <span property="familyName">Kurtz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Hamer</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+11</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ian</span> <span property="familyName">Bridges</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrea</span> <span property="familyName">Bartuli</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jean</span> <span property="familyName">Bergeron</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tamás</span> <span property="familyName">Szamosi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Saikat</span> <span property="familyName">Santra</span>, <span property="honorificSuffix">M.B., B.Chir.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Claudia</span> <span property="familyName">Stefanutti</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Olivier S.</span> <span property="familyName">Descamps</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susanne</span> <span property="familyName">Greber-Platzer</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ilse</span> <span property="familyName">Luirink</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John J.P.</span> <span property="familyName">Kastelein</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel</span> <span property="familyName">Gaudet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the HAUSER-RCT Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-11</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">August 29, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">1317</span>-<span property="pageEnd">1327</span></div><div class="doi">DOI: 10.1056/NEJMoa2019910</div><div class="core-enumeration"><a href="/toc/nejm/383/14"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">14</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRaul%2BD.%2BSantos%252C%2BAndrea%2BRuzza%252C%2BG.%2BKees%2BHovingh%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2019910%26title%3DEvolocumab%2Bin%2BPediatric%2BHeterozygous%2BFamilial%2BHypercholesterolemia%26publicationDate%3D10%252F01%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2019910" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRaul%2BD.%2BSantos%252C%2BAndrea%2BRuzza%252C%2BG.%2BKees%2BHovingh%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2019910%26title%3DEvolocumab%2Bin%2BPediatric%2BHeterozygous%2BFamilial%2BHypercholesterolemia%26publicationDate%3D10%252F01%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/5d1ba420-6770-4609-a23c-3dfba99948f9/nejmoa2019910.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2019910.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019910" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2019910" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2019910.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia. Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab (420 mg) or placebo. The primary end point was the percent change in LDL cholesterol level from baseline to week 24; key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 157 patients underwent randomization and received evolocumab (104 patients) or placebo (53 patients). At week 24, the mean percent change from baseline in LDL cholesterol level was −44.5% in the evolocumab group and −6.2% in the placebo group, for a difference of −38.3 percentage points (P&lt;0.001). The absolute change in the LDL cholesterol level was −77.5 mg per deciliter (−2.0 mmol per liter) in the evolocumab group and −9.0 mg per deciliter (−0.2 mmol per liter) in the placebo group, for a difference of −68.6 mg per deciliter (−1.8 mmol per liter) (P&lt;0.001). Results for all secondary lipid variables were significantly better with evolocumab than with placebo. The incidence of adverse events that occurred during the treatment period was similar in the evolocumab and placebo groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. (Funded by Amgen; HAUSER-RCT ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02392559" target="_blank">NCT02392559</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo005857/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005857" data-multimedia-filename="NEJMdo005857_600x400.jpg">
                <img src="/cms/asset/8c0117c5-4a68-4ac1-843f-a26ea7c404a2/media/NEJMdo005857_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo005857" data-multimedia-filename="NEJMdo005857_600x400.jpg">Evolocumab in Pediatric Heterozygous FH</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Familial hypercholesterolemia is a genetic condition characterized by an elevated plasma concentration of low-density lipoprotein (LDL) cholesterol starting at birth and an increased risk of premature atherosclerotic cardiovascular disease.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-1" href-manipulated="true" aria-label="Reference 1">1</a></sup> <a id="exam-tint-one-b"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-b">With an estimated prevalence of 1 in 250 in the general population, heterozygous familial hypercholesterolemia is the most frequent monogenic disorder and a major heritable cause of atherosclerotic cardiovascular disease worldwide.</span><sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup></div><div role="paragraph">Familial hypercholesterolemia is caused by variants in genes encoding proteins involved in the clearance of LDL particles. <a id="exam-tint-one-c"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-c">More than 90% of the patients with genetically confirmed familial hypercholesterolemia have mutations in the gene encoding the LDL receptor (<i>LDLR</i>). Familial hypercholesterolemia is also caused by mutations in genes encoding apolipoprotein B (<i>APOB</i>), proprotein convertase subtilisin–kexin type 9 (<i>PCSK9</i>), or LDL receptor adaptor protein 1 (<i>LDLRAP1</i>).</span><sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup> Naturally occurring loss-of-function <i>PCSK9</i> variants are associated with low LDL cholesterol levels starting at birth and a decreased incidence of atherosclerotic cardiovascular disease in adulthood.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Growing evidence suggests that the pathophysiological atherosclerotic changes begin early in life in patients with familial hypercholesterolemia and that reduction of LDL cholesterol levels in childhood may be important to prevent underlying atherosclerotic cardiovascular disease.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-1" href-manipulated="true" aria-label="Reference 4">4</a></sup> Statins are the standard preferred therapy for the pharmacologic treatment of familial hypercholesterolemia in pediatric patients. Ezetimibe may be added, and current guidelines recommend treatment initiation at the age of 8 or 10 years in heterozygous familial hypercholesterolemia.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5" id="body-ref-r5-1" href-manipulated="true">4,5</a></sup> Despite appropriate treatment, guideline-recommended LDL cholesterol levels are not achieved in some patients with familial hypercholesterolemia.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7" id="body-ref-r7-1" href-manipulated="true">5-7</a></sup></div><div role="paragraph">Evolocumab is a fully human monoclonal antibody directed against PCSK9. It prevents PCSK9 from degrading LDL receptor, which increases the availability of LDL receptor and thus reduces LDL cholesterol levels up to 60% in adults.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> Evolocumab was initially approved in 2015 to reduce LDL cholesterol levels in adults with hyperlipidemia, including familial hypercholesterolemia, and in 2017 to reduce the risk of myocardial infarction, stroke, and revascularization in adults with atherosclerotic cardiovascular disease.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">9-12</a></sup> Here, we describe the results of HAUSER-RCT, a randomized, placebo-controlled, parallel-group, phase 3 trial of evolocumab. The trial was designed to assess the efficacy and safety of evolocumab as an add-on therapy to appropriate statin treatment, with or without ezetimibe, in pediatric patients with familial hypercholesterolemia in whom LDL cholesterol goals had not been achieved.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">We conducted the trial from March 2016 through November 2019. The first patient was enrolled on March 24, 2016, and the last on May 30, 2019; the last visit with a trial patient was on November 25, 2019. The date of the database lock was February 25, 2020. Patients underwent screening and randomization at 47 sites across 23 countries in North America, Latin America, Europe, and the Asia–Pacific region. The trial consisted of a screening period with a maximum duration of 8 weeks followed by a 24-week double-blind treatment phase. Diagnosis of heterozygous familial hypercholesterolemia was made by means of genetic testing or according to applicable clinical diagnostic criteria for heterozygous familial hypercholesterolemia (criteria outlined by the Simon Broome Register Group, the Dutch Lipid Clinic Network, and the Make Early Diagnosis to Prevent Early Deaths [MEDPED] program). Biomarker measurements and pharmacogenetic testing were performed after written informed consent to participate in the trial had been obtained (from the patient or a legal guardian) in accordance with local regulations. An open-label extension study (HAUSER-OLE) is currently ongoing and was offered to patients who completed the present trial.</div><div role="paragraph">Amgen sponsored and designed the trial<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup>; the <a href="#ap1">protocol</a> and statistical analysis plan are available with the full text of this article at NEJM.org. The trial protocol and informed-consent form were reviewed and approved by independent ethics committees or institutional review boards at each trial site. Trial activities and oversight were conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonisation, and relevant regulatory requirements. An independent data monitoring committee and the independent biostatistical group oversaw efficacy and safety data on a regular basis. The first draft of the manuscript was written by an Amgen medical writer, in collaboration with and under the direction of the first, second, eighth, and last authors; all the coauthors interpreted the results and contributed to the development of subsequent manuscript drafts and vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients and Randomization</h3><div role="paragraph">Detailed information on patient eligibility criteria was reported previously<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-2" href-manipulated="true" aria-label="Reference 13">13</a></sup> (Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). Patients 10 to 17 years of age with heterozygous familial hypercholesterolemia who were following a low-fat diet, who had received stable lipid-lowering therapy for at least 4 weeks before screening, and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were screened. Patients were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of either evolocumab (420 mg) or placebo for 24 weeks. Randomization was stratified according to the LDL cholesterol level at the time of screening (&lt;160 vs. ≥160 mg per deciliter [4.1 mmol per liter]) and the age at baseline (&lt;14 vs. ≥14 years).</div></section><section id="sec-1-3"><h3>End Points</h3><div role="paragraph">The primary efficacy end point was the percent change in LDL cholesterol level from baseline to week 24. Secondary end points included the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24, the absolute change in LDL cholesterol level from baseline to week 24, and the percent changes in non–high-density lipoprotein (HDL) cholesterol level, apolipoprotein B level, the ratio of total cholesterol to HDL cholesterol, and the ratio of apolipoprotein B to apolipoprotein A1 from baseline to week 24. Details regarding other tertiary and exploratory end points are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>Safety</h3><div role="paragraph">Safety analyses included the incidence of adverse events that occurred during the treatment period. Laboratory assessments included levels of hormones and vitamins A, D, E, and K and the development of anti-evolocumab antibodies. Specific safety tests were conducted at baseline and week 24 to assess cognitive function (Cogstate battery of cognitive tests), pubertal growth and development (Tanner staging), carotid intima–media thickness for atherosclerosis progression,<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-3" href-manipulated="true" aria-label="Reference 13">13</a></sup> and changes on electrocardiography (ECG).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">A sample of 150 patients who were randomly assigned in a 2:1 ratio to receive evolocumab or placebo was calculated to be sufficient to generate 99% power to test the superiority of evolocumab (420 mg) over placebo for the primary end point. The sample size was calculated with the use of a two-sided t-test with a type I error rate of 0.05 and the following assumptions: a 40% lower level of LDL cholesterol with evolocumab than with placebo, a common standard deviation of 20%, and 20% of patients discontinuing the assigned regimen before trial completion (Fig. S1). Efficacy and safety analyses included all randomly assigned patients who received at least one dose of evolocumab or placebo. Additional information is provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From March 2016 through May 2019, a total of 158 patients underwent randomization, of whom 157 (99%) received either evolocumab (104 patients) or placebo (53 patients) (Fig. S2). The demographic and clinical characteristics of the patients at baseline were generally balanced between the two groups (<a href="#t1">Table 1</a>). The mean (±SD) age of the patients was 13.7±2.4 years, 88 patients (56%) were female, and 133 (85%) were White. A total of 18 patients (11%) had two or more risk factors for atherosclerotic cardiovascular disease; 52 (33%) had a first-degree family history of premature atherosclerotic cardiovascular disease. All the patients received a diagnosis of heterozygous familial hypercholesterolemia at screening. A total of 104 patients (66%) received a molecular diagnosis of familial hypercholesterolemia; of these, 100 patients (96%) had a mutation in <i>LDLR</i>, 3 (3%) had a mutation in <i>APOB</i>, and 1 (1%) had a mutation in <i>PCSK9</i>. At baseline, 124 patients (79%) were using high-intensity or moderate-intensity statins, and 21 (13%) were also taking ezetimibe. No changes in background lipid-lowering therapy were reported at any time during the trial.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/5457cdc7-d52e-4ee1-9589-929fc324e7ed/assets/images/large/nejmoa2019910_t1.jpg" height="3438" width="1512" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Evolocumab<br>(N=104)</th><th class="txxr-borders">Placebo<br>(N=53)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">13.7±2.3</td><td class="xxxr-borders">13.7±2.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;14 yr</td><td class="xxxx-borders">48 (46)</td><td class="xxxr-borders">25 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥14 yr</td><td class="xxxx-borders shading">56 (54)</td><td class="xxxr-borders shading">28 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">61 (59)</td><td class="xxxr-borders">27 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">White race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">89 (86)</td><td class="xxxr-borders shading">44 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Weight — kg</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">55.3 (48.0–68.8)</td><td class="xxxr-borders shading">53.3 (42.4–61.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">10th percentile</td><td class="xxxx-borders">35.7</td><td class="xxxr-borders">35.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">90th percentile</td><td class="xxxx-borders shading">79.0</td><td class="xxxr-borders shading">80.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Height — cm</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">161.5 (152.0–168.0)</td><td class="xxxr-borders shading">158.5 (148.0–165.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">10th percentile</td><td class="xxxx-borders">143.8</td><td class="xxxr-borders">143.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">90th percentile</td><td class="xxxx-borders shading">173.0</td><td class="xxxr-borders shading">175.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">BMI-for-age category — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Underweight</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Normal</td><td class="xxxx-borders">62 (60)</td><td class="xxxr-borders">36 (68)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Overweight</td><td class="xxxx-borders shading">21 (20)</td><td class="xxxr-borders shading">8 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Obese</td><td class="xxxx-borders">19 (18)</td><td class="xxxr-borders">7 (13)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Geographic region — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">North America</td><td class="xxxx-borders">12 (12)</td><td class="xxxr-borders">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Europe</td><td class="xxxx-borders shading">68 (65)</td><td class="xxxr-borders shading">35 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Latin America</td><td class="xxxx-borders">18 (17)</td><td class="xxxr-borders">8 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asia–Pacific</td><td class="xxxx-borders shading">6 (6)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiovascular risk factors — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Type 2 diabetes mellitus</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Family history of premature CHD</td><td class="xxxx-borders shading">31 (30)</td><td class="xxxr-borders shading">21 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Low HDL cholesterol</td><td class="xxxx-borders">40 (38)</td><td class="xxxr-borders">18 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Diagnosis of heterozygous FH — no. (%)</td><td class="xxxx-borders shading">104 (100)</td><td class="xxxr-borders shading">53 (100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Genetic</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>LDLR</i> mutation</td><td class="xxxx-borders shading">70 (67)</td><td class="xxxr-borders shading">30 (57)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left"><i>APOB</i> mutation</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>PCSK9</i> gain-of-function mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Clinical</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Simon Broome Register Group criteria</td><td class="xxxx-borders shading">9 (9)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Dutch Lipid Clinic Network criteria</td><td class="xxxx-borders">22 (21)</td><td class="xxxr-borders">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">MEDPED program criteria</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">4 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Statin use — no. (%)</td><td class="xxxx-borders">104 (100)</td><td class="xxxr-borders">52 (98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High intensity</td><td class="xxxx-borders shading">19 (18)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Moderate intensity</td><td class="xxxx-borders">63 (61)</td><td class="xxxr-borders">35 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Low intensity or unknown intensity</td><td class="xxxx-borders shading">22 (21)</td><td class="xxxr-borders shading">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Ezetimibe — no. (%)</td><td class="xxxx-borders">13 (12)</td><td class="xxxr-borders">8 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Lipid variables<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">LDL cholesterol — mg/dl</td><td class="xxxx-borders">185.0±45.0</td><td class="xxxr-borders">183.0±47.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">203.8±47.3</td><td class="xxxr-borders shading">200.2±48.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders">250.7±47.0</td><td class="xxxr-borders">247.3±49.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">46.8±12.0</td><td class="xxxr-borders shading">47.2±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median triglycerides (IQR) — mg/dl</td><td class="xxxx-borders">86.8 (63.8–117.0)</td><td class="xxxr-borders">78.0 (62.5–101.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders shading">50.5 (18.0–126.5)</td><td class="xxxr-borders shading">34.0 (21.0–147.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">PCSK9 — ng/ml</td><td class="xbxx-borders">277.2±92.1</td><td class="xbxr-borders">294.2±101.3</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Patients were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of either evolocumab (420 mg) or placebo for 24 weeks. Data from all 157 patients were used for analysis. To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. Percentages may not total 100 because of rounding. CHD denotes coronary heart disease, FH familial hypercholesterolemia, HDL high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, and MEDPED Make Early Diagnosis to Prevent Early Deaths.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. BMI-for-age categories are based on expert committee recommendations<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15 r16" id="body-ref-r16" href-manipulated="true">14-16</a></sup> (underweight, &lt;5th percentile; normal, ≥5th percentile to &lt;85th percentile; overweight, ≥85th percentile to &lt;95th percentile; and obese, ≥95th percentile).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Shown are hypertension and diabetes diagnoses as provided by the investigators and entered in the trial clinical research form; no definition of hypertension was specifically used in the trial. A low HDL cholesterol level was defined as less than 40 mg per deciliter (1.0 mmol per liter) in patients 10 years of age to younger than 16 years of age, less than 40 mg per deciliter in male patients 16 years of age or older, and less than 50 mg per deciliter (1.3 mmol per liter) in female patients 16 years of age or older.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">For lipoprotein(a), 2 patients in the placebo group had missing values; for proprotein convertase subtilisin–kexin type 9 (PCSK9), 7 patients in the evolocumab group and 1 patient in the placebo group had missing values.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">The mean (±SD) level of LDL cholesterol at baseline was 184.3±45.6 mg per deciliter (4.8±1.2 mmol per liter). Results for the primary and secondary efficacy end points were significantly better with evolocumab than with placebo (P&lt;0.001 for all comparisons, with adjustment for multiple comparisons). At week 24, the mean percent change in LDL cholesterol level was −44.5% in the evolocumab group and −6.2% in the placebo group, for a difference of −38.3 percentage points (95% confidence interval [CI], −45.5 to −31.1). The mean absolute change in LDL cholesterol level from baseline to week 24 was −77.5 mg per deciliter (−2.0 mmol per liter) in the evolocumab group and −9.0 mg per deciliter (−0.2 mmol per liter) in the placebo group, for a difference of −68.6 mg per deciliter (95% CI, −83.1 to −54.0) (−1.8 mmol per liter [95% CI, −2.1 to −1.4]) (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t2.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/505b892e-2303-4944-807c-3f5996be8990/assets/images/large/nejmoa2019910_t2.jpg" height="1338" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Evolocumab<br>(N=104)<a href="#t2fn1" role="doc-noteref">*</a></th><th class="txxx-borders">Placebo<br>(N=53)<a href="#t2fn1" role="doc-noteref">*</a></th><th class="txxx-borders">Difference<br>(95% CI)<a href="#t2fn1" role="doc-noteref">*</a><a href="#t2fn2" role="doc-noteref">†</a></th><th class="txxr-borders">Adjusted P Value</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in LDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−44.5 (−48.8 to −40.3)</td><td class="xxxx-borders shading">−6.2 (−12.3 to −0.2)</td><td class="xxxx-borders shading">−38.3 (−45.5 to −31.1)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in LDL cholesterol from baseline to wk 22 and 24 (95% CI)</td><td class="xxxx-borders">−48.0 (−51.7 to −44.2)</td><td class="xxxx-borders">−5.9 (−11.1 to −0.6)</td><td class="xxxx-borders">−42.1 (−48.3 to −35.8)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Absolute change in LDL cholesterol from baseline to wk 24 (95% CI) — mg/dl</td><td class="xxxx-borders shading">−77.5 (−86.1 to −68.9)</td><td class="xxxx-borders shading">−9.0 (−21.1 to 3.2)</td><td class="xxxx-borders shading">−68.6 (−83.1 to −54.0)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in non-HDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders">−41.2 (−45.2 to −37.2)</td><td class="xxxx-borders">−6.1 (−11.8 to −0.5)</td><td class="xxxx-borders">−35.0 (−41.8 to −28.3)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in apolipoprotein B from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−34.9 (−38.6 to −31.1)</td><td class="xxxx-borders shading">−2.4 (−7.7 to 3.0)</td><td class="xxxx-borders shading">−32.5 (−38.8 to −26.1)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in ratio of total cholesterol to HDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders">−35.0 (−38.6 to −31.4)</td><td class="xxxx-borders">−4.7 (−9.8 to 0.5)</td><td class="xxxx-borders">−30.3 (−36.4 to −24.2)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in ratio of apolipoprotein B to apolipoprotein A1 from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−37.0 (−40.9 to −33.2)</td><td class="xxxx-borders shading">−0.6 (−6.2 to 4.9)</td><td class="xxxx-borders shading">−36.4 (−43.0 to −29.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in lipoprotein(a) from baseline to wk 24 (95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">−7.4 (−20.1 to 5.3)</td><td class="xxxx-borders">1.7 (−17.0 to 20.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Percent change in lipoprotein(a) from baseline to wk 22 and 24 (95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders shading">−10.3 (−18.7 to −1.9)</td><td class="xbxx-borders shading">1.6 (−10.4 to 13.7)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary Efficacy End Points.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Shown are least-squares means from the repeated-measures model, which includes trial group, stratification factor of age at baseline and LDL cholesterol level at the time of screening (from the interactive voice-response system), scheduled visit, and the interaction of treatment with scheduled visit as covariates.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The difference is the value in the evolocumab group minus the value in the placebo group. Differences are expressed as percentage points, except for the absolute change in LDL cholesterol level (expressed as milligrams per deciliter).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Lipoprotein(a) was a tertiary end point.</div></div></div></figcaption></figure></div><div role="paragraph">The efficacy of evolocumab for LDL cholesterol reduction was maintained throughout the trial (<a href="#f1">Figure 1</a>). At weeks 22 and 24, the mean percent change from baseline in LDL cholesterol level was −48.0% in the evolocumab group and −5.9% in the placebo group, for a difference of −42.1 percentage points (<a href="#t2">Table 2</a>). An LDL cholesterol reduction of more than 50% at week 22 was achieved in 60 of 97 patients (62%) in the evolocumab group and 0 of 49 patients in the placebo group. Similarly, at week 24, a total of 43 of 96 patients (45%) in the evolocumab group and 1 of 44 patients (2%) in the placebo group had an LDL cholesterol reduction of more than 50% (Table S2). An LDL cholesterol level of less than 130 mg per deciliter at week 22 was achieved in 77 of 97 patients (79%) in the evolocumab group and 7 of 49 patients (14%) in the placebo group (Table S2). At week 24, an LDL cholesterol level of less than 130 mg per deciliter was achieved in 71 of 96 patients (74%) in the evolocumab group and 10 of 44 patients (23%) in the placebo group (Table S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f1.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/ed8a5984-4314-4602-b625-3ba9ad4f18bd/assets/images/large/nejmoa2019910_f1.jpg" height="1433" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Mean Percent Change in Low-Density Lipoprotein (LDL) Cholesterol Level.</div><div class="notes"><div role="doc-footnote">Shown are the unadjusted means and 95% confidence intervals for the percent change in LDL cholesterol level from baseline through the end of the trial at each scheduled visit. No imputation was used for missing values. Arrows indicate the subcutaneous administration of evolocumab (420 mg) or placebo at day 1, week 4, week 8, week 12, week 16, and week 20. 𝙸 bars indicate standard errors.</div></div></figcaption></figure></div><div role="paragraph">Evolocumab showed a benefit with respect to other secondary lipid-related end points, including non-HDL cholesterol and apolipoprotein B (<a href="#t2">Table 2</a>). Results of sensitivity analyses of the primary and secondary end points, including an analysis in which assessments were made outside the prespecified time window of week 24 (Table S3), were consistent with the results of the primary analysis (Table S3). The primary end-point analysis at the patient level showed a consistently greater reduction in LDL cholesterol levels with evolocumab than with placebo (Fig. S3).</div><div role="paragraph">Evolocumab showed a benefit with respect to the primary and secondary efficacy end points in additional subgroup analyses (<a href="#f2">Figure 2</a>). The effect of evolocumab on LDL cholesterol lowering was similar in patients younger than 14 years of age and those 14 years of age or older (<a href="#f2">Figure 2</a>). Furthermore, the mean percent decrease in the lipoprotein(a) level at week 24 and at weeks 22 and 24 was numerically greater with evolocumab than with placebo (<a href="#t2">Table 2</a>). Evolocumab treatment resulted in a reduction in the serum levels of circulating unbound PCSK9, with maximal suppression of PCSK9 and LDL cholesterol at week 22 correlating with a peak concentration of evolocumab (Fig. S4).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f2.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/b980666a-b138-49d9-96ab-06f52e5fc63d/assets/images/large/nejmoa2019910_f2.jpg" height="2029" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Efficacy End Points.</div><div class="notes"><div role="doc-footnote">Shown are forest plots of the between-group difference (evolocumab minus placebo) in the percent change in LDL cholesterol level from baseline to the mean of weeks 22 and 24 and to week 24 according to subgroup. A repeated-measures model was used for the analysis. To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. PCSK9 denotes proprotein convertase subtilisin–kexin type 9.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph"><a id="exam-tint-three-b"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-b">The incidence of adverse events that occurred during the treatment period was similar in the evolocumab group and the placebo group.</span> A total of 64 patients (62%) in the evolocumab group and 34 (64%) in the placebo group reported at least one adverse event (<a href="#t3">Table 3</a>). One patient (1%) in the evolocumab group reported a serious adverse event of cholelithiasis that was not considered by the investigators and data monitoring committee to be related to the drug; another patient in the evolocumab group had a nonserious treatment-related adverse event of arthropathy that led to discontinuation of the drug (<a href="#t3">Table 3</a>). The most common adverse events (&gt;2% of the patients in either group) with a higher incidence (by &gt;1 percentage point) in the evolocumab group than in the placebo group were headache, oropharyngeal pain, influenza, influenza-type illness, upper respiratory tract infection, and constipation. In the evolocumab group, an injection-site reaction occurred in 1 patient (1%), as compared with no patients in the placebo group (<a href="#t3">Table 3</a>). Four patients in the evolocumab group (4%) discontinued treatment with the drug: 1 had a nonserious treatment-related adverse event of arthropathy (mentioned above), 2 requested discontinuation, and 1 missed a scheduled visit at which the final dose would have been administered.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t3.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/ff9757b9-0ca0-4ceb-8a09-aecf0b20a2fc/assets/images/large/nejmoa2019910_t3.jpg" height="1711" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Evolocumab<br>(N=104)</th><th class="txxr-borders">Placebo<br>(N=53)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>no. of patients (%)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">64 (62)</td><td class="xxxr-borders shading">34 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of regimen</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Serious</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonserious</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most common adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">12 (12)</td><td class="xxxr-borders shading">6 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">11 (11)</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Oropharyngeal pain</td><td class="xxxx-borders shading">7 (7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Influenza</td><td class="xxxx-borders">6 (6)</td><td class="xxxr-borders">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">6 (6)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">5 (5)</td><td class="xxxr-borders">4 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">3 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">3 (3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Influenza-like illness</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Laboratory results at wk 24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Aminotransferase level &gt;3× ULN</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Creatine kinase level &gt;5× ULN</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Development of anti-evolocumab antibodies<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">0</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="caption">Safety Data.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">ULN denotes the upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Anti-evolocumab antibody assessment by means of an electrochemiluminescence-based immunoassay was performed at day 1 (randomization), week 12, and week 24 (end of the trial). None of the patients tested positive at any time point.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Additional Efficacy and Safety Assessments</h3><div role="paragraph">At week 24, mean changes from baseline in pubertal development (Tanner stage for male patients and female patients [Table S4]) and growth variables (height, weight, and body-mass index [Table S9]) were similar in the evolocumab and placebo groups. Results for laboratory variables (including levels of steroid hormones, fat-soluble vitamins [vitamins A, D, E, and K], glucose, and glycated hemoglobin) were similar in the two groups at week 24 (Table S5). Changes from baseline in carotid intima–media thickness (Table S6), neurologic assessment with the Cogstate battery of cognitive tests (Table S7), and ECG measures (Table S8) at week 24 were similar in the evolocumab and placebo groups. <a id="exam-tint-three-a"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a">Anti-evolocumab antibodies developed in no patients during the trial, and no onset of diabetes was observed</span> (<a href="#t3">Table 3</a>).</div></section></section><section id="sec-3"><h2>Discussion</h2><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">In this multicenter, randomized, controlled trial involving pediatric patients with heterozygous familial hypercholesterolemia, the PCSK9 inhibitor evolocumab, when added to statin therapy with or without ezetimibe, was associated with a significantly greater reduction in the LDL cholesterol level from baseline to week 24 than placebo (difference, −38.3 percentage points or −68.6 mg per deciliter). At weeks 22 and 24, the between-group difference in the mean percent change from baseline in LDL cholesterol level was −42.1 percentage points. Significant benefits with respect to other lipid variables in this pediatric population were also observed. No safety concerns emerged from the analyses of the safety data.</span></div><div role="paragraph">Statins, ezetimibe, and bile acid–binding resins are currently approved therapies to lower LDL cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia. Despite these medications, a recent European study showed that guideline-recommended LDL cholesterol goals of less than 130 mg per deciliter, more modest than those for adults,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-3" href-manipulated="true" aria-label="Reference 1">1</a></sup> were not achieved in 41 to 56% of these pediatric patients in most countries, although treatment may not have been appropriate in all the patients studied.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup> In the present trial, 124 patients (79%) were receiving high-intensity or moderate-intensity statins, and only a minority (21 patients [13%]) were receiving ezetimibe. Background lipid-lowering treatment reflected the diversity of the real-life management of pediatric familial hypercholesterolemia in the 23 countries from which the participants originated.</div><div role="paragraph">Statins are currently the first-line treatment for pediatric patients who may need pharmacologic therapy. Results of a recent study suggest that early initiation of statin treatment reduces subclinical atherosclerosis progression (as measured by carotid intima–media thickness), which is likely to result in a decrease in clinical atherosclerotic cardiovascular disease events at later stages of life.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> <a id="exam-tint-one-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="one-d">Despite the fact that the recommended statin dose in the pediatric population is lower than in adults, the care of the majority of pediatric patients with familial hypercholesterolemia will be adequately managed with statins with or without ezetimibe and will not involve additional treatment.</span> However, LDL cholesterol goals are not attained in some patients owing to limited drug response, side effects, or poor treatment adherence. The results of the present trial suggest that if an additional therapy is indicated, evolocumab might be considered. <a id="exam-tint-one-a"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="one-a">Newer potential treatments such as bempedoic acid,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> gemcabene,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> small interfering RNA against PCSK9 (inclisiran),<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> and the monoclonal antibody against angiopoietin-like 3 inhibitor (evinacumab)<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> have not yet been evaluated in pediatric patients with heterozygous familial hypercholesterolemia.</span></div><div role="paragraph">A few studies have examined the efficacy and safety of PCSK9 inhibitors in a limited number of pediatric patients with heterozygous familial hypercholesterolemia. The Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities (TESLA)<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> and the Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG)<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> included a total of 15 pediatric patients, all of whom had homozygous familial hypercholesterolemia. In this small group of patients, the safety profile of evolocumab was similar to that of placebo, and results for LDL cholesterol levels and other lipid variables were better with evolocumab. The ODYSSEY KIDS study, a phase 2, open-label, dose-finding study involving 42 pediatric patients with heterozygous familial hypercholesterolemia, showed a significant reduction in LDL cholesterol levels from baseline to week 8 with alirocumab.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup></div><div role="paragraph">Throughout the present 6-month trial, 153 of 157 patients (97%) received all planned doses of evolocumab or placebo, and among the 104 who received evolocumab, binding or neutralizing antibodies developed in no patients. No trends indicative of clinically important treatment-related laboratory or vital-sign abnormalities, abnormal physical examination findings (including findings on growth and pubertal development), or cognitive changes were observed. Moreover, there was no evidence of clinically relevant effects of evolocumab on steroid hormone biosynthesis or on levels of vitamins (A, D, E, and K). Both the evolocumab and placebo groups received subcutaneous injections every 4 weeks. No patient dropped out owing to adverse events related to injection.</div><div role="paragraph">Our results include safety and efficacy data from this randomized, placebo-controlled trial of a PCSK9 inhibitor in pediatric patients with heterozygous familial hypercholesterolemia. The response to and safety of evolocumab at 24 weeks were consistent in all prespecified subgroups. <a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="three-c three-d">However, the present trial has certain limitations. Despite the fact that it was conducted in 23 countries and five continents, there was a preponderance of White patients. The relatively short duration of the trial precluded the assessment of the effects of evolocumab on carotid intima–media thickness, neurocognition, and growth and development. The long-term safety and efficacy of evolocumab in the management of familial hypercholesterolemia in pediatric patients will require further study.</span></div><div role="paragraph">We found that monthly evolocumab provided substantial LDL cholesterol lowering at 24 weeks when added to background lipid-lowering therapy in pediatric patients with heterozygous familial hypercholesterolemia.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on August 29, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Amgen</span>.</div><div role="paragraph">Dr. Santos reports receiving consulting fees and lecture fees from AstraZeneca, Aché, Libbs, and Novo Nordisk, grant support, consulting fees, and lecture fees from Amgen and Sanofi–Regeneron Pharmaceuticals, lecture fees from EMS, Merck, Merck Sharp &amp; Dohme, PTC Therapeutics, and Pfizer, fees for coordinating a research protocol from Esperion, grant support from Kowa, and consulting fees from Abbott; Dr. Ruzza, being employed by and owning stock in Amgen and holding pending patent 63/032451 on PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders; Dr. Hovingh, receiving grant support, consulting fees, fees for serving on a speakers bureau, and advisory board fees, all paid to his institution, from Aegerion Pharmaceuticals, Amgen, Regeneron Pharmaceuticals, and Sanofi, receiving grant support, paid to his institution, from AstraZeneca, Eli Lilly, Genzyme, Kowa, Pfizer, Roche, the Medicines Company, and Ionis Pharmaceuticals, and being employed by Novo Nordisk; Dr. Kurtz, being employed by and owning stock in Amgen; Dr. Hamer and Mr. Bridges, being employed by and owning stock in Amgen and holding pending patent 63/032451 on PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders; Dr. Bergeron, receiving grant support, advisory board fees, and lecture fees from Amgen and Sanofi, grant support from Regeneron Pharmaceuticals, Akcea Therapeutics–Ionis Pharmaceuticals, the Medicines Company, Kowa, Bayer, Novartis, and Novo Nordisk, and advisory board fees from Akcea Therapeutics; Dr. Descamps, receiving grant support, honoraria, and advisory board fees from Amgen, Sanofi, and Merck Sharp &amp; Dohme and honoraria from Servier, Mylan, Fresenius Medical Care Belgium, and Eurogenerics; Dr. Kastelein, receiving consulting fees from AstraZeneca, CiVi Biopharma, CSL Behring, Draupnir Bio, Esperion, Gemphire Therapeutics, Madrigal Pharmaceuticals, Matinas BioPharma, NorthSea Therapeutics, Novo Nordisk, Novartis, Reneneron Pharmaceuticals, REGENXBIO, Staten Biotechnology, 89bio, Omeicos Therapeutics, and Serometrix; and Dr. Gaudet, receiving grant support from Esperion, Gemphire Therapeutics, Pfizer, and the Medicines Company and grant support and consulting fees from HDL Therapeutics, Regeneron Pharmaceuticals, and Sanofi. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients, their families, and all the investigators involved in this study. Medical writing and editorial assistance with a previous version of the manuscript, under the direction of the authors, was provided by Qais Al-Hadid, an Amgen medical writer.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2019910_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2019910/suppl_file/nejmoa2019910_protocol.pdf" download="nejmoa2019910_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2019910_protocol.pdf" data-doi="10.1056/NEJMoa2019910">Download</a></li><li>3.91 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2019910_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2019910/suppl_file/nejmoa2019910_appendix.pdf" download="nejmoa2019910_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2019910_appendix.pdf" data-doi="10.1056/NEJMoa2019910">Download</a></li><li>649.26 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2019910_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2019910/suppl_file/nejmoa2019910_disclosures.pdf" download="nejmoa2019910_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2019910_disclosures.pdf" data-doi="10.1056/NEJMoa2019910">Download</a></li><li>445.71 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2019910_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2019910/suppl_file/nejmoa2019910_data-sharing.pdf" download="nejmoa2019910_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2019910_data-sharing.pdf" data-doi="10.1056/NEJMoa2019910">Download</a></li><li>70.88 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. <em>Nat Rev Dis Primers</em> 2017;3:17093-17093.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrdp.2017.93" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29219151/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417650300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia.&amp;publication_year=2017&amp;journal=Nat+Rev+Dis+Primers&amp;pages=17093-17093&amp;doi=10.1038%2Fnrdp.2017.93&amp;pmid=29219151" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] LDL receptor adaptor protein 1 (LDLRAP1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] more modest than those for adults, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. <em>Circulation</em> 2020;141:1742-1759.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32468833/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538162700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+familial+hypercholesterolemia+among+the+general+population+and+patients+with+atherosclerotic+cardiovascular+disease%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=Circulation&amp;pages=1742-1759&amp;doi=10.1161%2FCIRCULATIONAHA.119.044795&amp;pmid=32468833" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in <i>PCSK9</i>, low LDL, and protection against coronary heart disease. <em>N Engl J Med</em> 2006;354:1264-1272.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa054013&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16554528/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236164200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sequence+variations+in+PCSK9%2C+low+LDL%2C+and+protection+against+coronary+heart+disease.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=1264-1272&amp;doi=10.1056%2FNEJMoa054013&amp;pmid=16554528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <em>Eur Heart J</em> 2015;36:2425-2437.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehv157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26009596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362044000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia+in+children+and+adolescents%3A+gaining+decades+of+life+by+optimizing+detection+and+treatment.&amp;publication_year=2015&amp;journal=Eur+Heart+J&amp;pages=2425-2437&amp;doi=10.1093%2Feurheartj%2Fehv157&amp;pmid=26009596" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterozygous familial hypercholesterolemia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <em>Circulation</em> 2019;139(25):e1082-e1143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471794100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2018+AHA%2FACC%2FAACVPR%2FAAPA%2FABC%2FACPM%2FADA%2FAGS%2FAPhA%2FASPC%2FNLA%2FPCNA+guideline+on+the+management+of+blood+cholesterol%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=e1082-e1143&amp;pmid=30586774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] heterozygous familial hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with familial hypercholesterolemia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <em>Eur Heart J</em> 2020;41:111-188.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605984300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias%3A+lipid+modification+to+reduce+cardiovascular+risk.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;pages=111-188&amp;doi=10.1093%2Feurheartj%2Fehz455&amp;pmid=31504418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Ramaswami U, Futema M, Bogsrud MP, et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <em>Atherosclerosis</em> 2020;292:178-187.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2019.11.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31809987/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503400300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+characteristics+at+diagnosis+and+treatment+of+children+with+heterozygous+familial+hypercholesterolaemia+%28FH%29+from+eight+European+countries.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=178-187&amp;doi=10.1016%2Fj.atherosclerosis.2019.11.012&amp;pmid=31809987" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with familial hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] appropriate in all the patients studied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. <em>J Clin Pharmacol</em> 2017;57:7-32.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.766" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27195910/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392014300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+monoclonal+antibodies%3A+modern+management+of+hypercholesterolemia.&amp;publication_year=2017&amp;journal=J+Clin+Pharmacol&amp;pages=7-32&amp;doi=10.1002%2Fjcph.766&amp;pmid=27195910" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <em>N Engl J Med</em> 2017;376:1713-1722.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1615664&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28304224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400442300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolocumab+and+clinical+outcomes+in+patients+with+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1713-1722&amp;doi=10.1056%2FNEJMoa1615664&amp;pmid=28304224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. <em>J Am Coll Cardiol</em> 2020;75:565-574.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.12.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32057369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512903000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+evolocumab+in+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=565-574&amp;doi=10.1016%2Fj.jacc.2019.12.020&amp;pmid=32057369" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with Genetic LDL Disorders (TAUSSIG) </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2015;385:331-340.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61399-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25282519/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348509000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+evolocumab+%28AMG+145%29+in+heterozygous+familial+hypercholesterolaemia+%28RUTHERFORD-2%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=331-340&amp;doi=10.1016%2FS0140-6736%2814%2961399-4&amp;pmid=25282519" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. <em>J Am Coll Cardiol</em> 2019;74:2132-2146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.08.1024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31648705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491235900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+efficacy+and+safety+of+evolocumab+in+patients+with+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Am+Coll+Cardiol&amp;pages=2132-2146&amp;doi=10.1016%2Fj.jacc.2019.08.1024&amp;pmid=31648705" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Langslet G, Gidding SS, et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. <em>J Clin Lipidol</em> 2018;12:1199-1207.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacl.2018.05.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30318065/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000447815400020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+tolerability+of+evolocumab+in+pediatric+patients+with+heterozygous+familial+hypercholesterolemia%3A+rationale+and+design+of+the+HAUSER-RCT+study.&amp;publication_year=2018&amp;journal=J+Clin+Lipidol&amp;pages=1199-1207&amp;doi=10.1016%2Fj.jacl.2018.05.007&amp;pmid=30318065" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Amgen sponsored and designed the trial </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] criteria was reported previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] thickness for atherosclerosis progression, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Barlow SE, Expert Committee. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. <em>Pediatrics</em> 2007;120:Suppl 4:S164-S192.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1542/peds.2007-2329C" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18055651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253378300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Expert+Committee+recommendations+regarding+the+prevention%2C+assessment%2C+and+treatment+of+child+and+adolescent+overweight+and+obesity%3A+summary+report.&amp;publication_year=2007&amp;journal=Pediatrics&amp;pages=S164-S192&amp;doi=10.1542%2Fpeds.2007-2329C&amp;pmid=18055651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Cote AT, Harris KC, Panagiotopoulos C, Sandor GG, Devlin AM. Childhood obesity and cardiovascular dysfunction. <em>J Am Coll Cardiol</em> 2013;62:1309-1319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2013.07.042" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23954339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325005000002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Childhood+obesity+and+cardiovascular+dysfunction.&amp;publication_year=2013&amp;journal=J+Am+Coll+Cardiol&amp;pages=1309-1319&amp;doi=10.1016%2Fj.jacc.2013.07.042&amp;pmid=23954339" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Whitlock EP, Williams SB, Gold R, Smith PR, Shipman SA. Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. <em>Pediatrics</em> 2005;116(1):e125-e144.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1542/peds.2005-0242" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15995013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230207500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+and+interventions+for+childhood+overweight%3A+a+summary+of+evidence+for+the+US+Preventive+Services+Task+Force.&amp;publication_year=2005&amp;journal=Pediatrics&amp;pages=e125-e144&amp;doi=10.1542%2Fpeds.2005-0242&amp;pmid=15995013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. <em>N Engl J Med</em> 2019;381:1547-1556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1816454&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31618540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491085100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=20-Year+follow-up+of+statins+in+children+with+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1547-1556&amp;doi=10.1056%2FNEJMoa1816454&amp;pmid=31618540" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. <em>JAMA</em> 2019;322:1780-1788.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.16585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31714986/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000498675500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+bempedoic+acid+vs+placebo+added+to+maximally+tolerated+statins+on+low-density+lipoprotein+cholesterol+in+patients+at+high+risk+for+cardiovascular+disease%3A+the+CLEAR+Wisdom+randomized+clinical+trial.&amp;publication_year=2019&amp;journal=JAMA&amp;pages=1780-1788&amp;doi=10.1001%2Fjama.2019.16585&amp;pmid=31714986" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Durst R, Lepor N, et al. Usefulness of gemcabene in homozygous familial hypercholesterolemia (from COBALT-1). <em>Am J Cardiol</em> 2019;124:1876-1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjcard.2019.09.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31685212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503909900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Usefulness+of+gemcabene+in+homozygous+familial+hypercholesterolemia+%28from+COBALT-1%29.&amp;publication_year=2019&amp;journal=Am+J+Cardiol&amp;pages=1876-1880&amp;doi=10.1016%2Fj.amjcard.2019.09.010&amp;pmid=31685212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2020;382:1520-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1913805&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32197277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527733300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inclisiran+for+the+treatment+of+heterozygous+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1520-1530&amp;doi=10.1056%2FNEJMoa1913805&amp;pmid=32197277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2017;377:296-297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMc1705994&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28723334/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+inhibition+in+homozygous+familial+hypercholesterolemia.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=296-297&amp;doi=10.1056%2FNEJMc1705994&amp;pmid=28723334" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2015;385:341-350.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61374-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25282520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348509000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+PCSK9+with+evolocumab+in+homozygous+familial+hypercholesterolaemia+%28TESLA+Part+B%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=341-350&amp;doi=10.1016%2FS0140-6736%2814%2961374-X&amp;pmid=25282520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Daniels S, Caprio S, Chaudhari U, et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. <em>J Clin Lipidol</em> 2020;14:322-330.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacl.2020.03.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32331936/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000540548500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+alirocumab+in+pediatric+patients+with+heterozygous+familial+hypercholesterolemia%3A+the+ODYSSEY+KIDS+study.&amp;publication_year=2020&amp;journal=J+Clin+Lipidol&amp;pages=322-330.e5&amp;doi=10.1016%2Fj.jacl.2020.03.001&amp;pmid=32331936" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/14"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">14</span></span> • <span property="datePublished">October 1, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1317</span>-<span property="pageEnd">1327</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: August 29, 2020</div><div><b class="core-label">Published in issue</b>: October 1, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/cardiology-general" alt="View article keyword Cardiology General" data-interactiontype="article_recirculation_click">Cardiology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/genetics-general" alt="View article keyword Genetics General" data-interactiontype="article_recirculation_click">Genetics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/lipids" alt="View article keyword Lipids" data-interactiontype="article_recirculation_click">Lipids</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pediatrics-general" alt="View article keyword Pediatrics General" data-interactiontype="article_recirculation_click">Pediatrics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Raul D.</span> <span property="familyName">Santos</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-9860-6582" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-9860-6582</a></span>, <span property="author" typeof="Person"><span property="givenName">Andrea</span> <span property="familyName">Ruzza</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">G. Kees</span> <span property="familyName">Hovingh</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-8043-951X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-8043-951X</a></span>, <span property="author" typeof="Person"><span property="givenName">Albert</span> <span property="familyName">Wiegman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">François</span> <span property="familyName">Mach</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christopher E.</span> <span property="familyName">Kurtz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Hamer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ian</span> <span property="familyName">Bridges</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrea</span> <span property="familyName">Bartuli</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jean</span> <span property="familyName">Bergeron</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tamás</span> <span property="familyName">Szamosi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Saikat</span> <span property="familyName">Santra</span>, <span property="honorificSuffix">M.B., B.Chir.</span></span>, <span property="author" typeof="Person"><span property="givenName">Claudia</span> <span property="familyName">Stefanutti</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Olivier S.</span> <span property="familyName">Descamps</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Susanne</span> <span property="familyName">Greber-Platzer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ilse</span> <span property="familyName">Luirink</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John J.P.</span> <span property="familyName">Kastelein</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Daniel</span> <span property="familyName">Gaudet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, for <span property="author" typeof="Person">the HAUSER-RCT Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Lipid Clinic Heart Institute, University of São Paulo Medical School Hospital and Hospital Israelita Albert Einstein, São Paulo (R.D.S.); Amgen, Thousand Oaks, CA (A.R., C.E.K, A.H.); the Departments of Vascular Medicine (G.K.H., J.J.P.K.) and Pediatrics (A.W., I.L.), Amsterdam UMC, Amsterdam; the Cardiology Department, Geneva University Hospital, Geneva (F.M.); the Biostatistics Department, Amgen, Cambridge (I.B.), and the Department of Clinical Inherited Metabolic Disorders, Birmingham Children’s Hospital, Birmingham (S.S.) — both in the United Kingdom; the Rare Diseases and Clinical Genetics Unit, Academic Pediatric Department, Bambino Gesù Children’s Hospital (A.B.), and the Department of Molecular Medicine, Umberto I Hospital, Sapienza University of Rome (C.S.), Rome; the Lipid Clinic, Department of Medicine, Centre Hospitalier Universitaire de Québec–Université Laval, Quebec (J.B.), and the Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Chicoutimi, QC (D.G.) — both in Canada; the 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary (T.S.); the Department of Internal Medicine, Centres Hospitaliers Jolimont, La Louvière, Belgium (O.S.D.); and the Division of Pediatric Pulmonology, Allergology, and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna (S.G.-P.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Gaudet at the Department of Medicine, Université de Montréal and ECOGENE-21 Clinical Research Center, 930 Jacques-Cartier, Chicoutimi, QC G7H 7K9, Canada, or at <a href="mailto:daniel.gaudet@umontreal.ca">daniel.gaudet@umontreal.ca</a>; or to Dr. Santos at the Lipid Clinic Heart Institute, University of São Paulo Medical School Hospital, and Hospital Israelita Albert Einstein, São Paulo 05403-900, Brazil, or at <a href="mailto:rauldsf@gmail.com">rauldsf@gmail.com</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the HAUSER-RCT investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">138</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2019910" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="c2e58997-eef7-1975-e371-48368d7e4bbf"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644" style="display:inline-block;">
                <img alt="Article has an altmetric score of 113" src="https://badges.altmetric.com/?size=320&amp;score=113&amp;types=mabttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_c2e58997-eef7-1975-e371-48368d7e4bbf" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644&amp;tab=news">
          Picked up by <b>6</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644&amp;tab=twitter">
          Posted by <b>92</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89117644&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>170</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d64be1069800ae-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2019910"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-14%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2019910%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="138" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mayank Jha, </li><li class="list-inline-item cited-by__entry__author">Siddharth Pravin Agrawal, </li><li class="list-inline-item cited-by__entry__author">Darshilkumar Maheta, </li><li class="list-inline-item cited-by__entry__author">Priyadarshini Bhattacharjee, </li><li class="list-inline-item cited-by__entry__author">Hritvik Jain, </li><li class="list-inline-item cited-by__entry__author">Jerome Zacks, </li><li class="list-inline-item cited-by__entry__author">William H. Frishman, </li><li class="list-inline-item cited-by__entry__author">Wilbert S. Aronow, </li></ul><span class="cited-by__entry__title">Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Expert Opinion on Biological Therapy, </span><span class="cited-by__entry__page-range">(1-11), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14712598.2025.2511063" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14712598.2025.2511063</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14712598.2025.2511063" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexios-Fotios A. Mentis, </li><li class="list-inline-item cited-by__entry__author">Maria Dalamaga, </li></ul><span class="cited-by__entry__title">Rare biochemical &amp; genetic conditions: clues for broader mechanistic insights, </span><span class="cited-by__entry__series-title">Cellular and Molecular Life Sciences, </span><span class="cited-by__entry__volume"><strong>82</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s00018-025-05652-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00018-025-05652-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00018-025-05652-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lorenzo Da Dalt, </li><li class="list-inline-item cited-by__entry__author">Andrea Baragetti, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Danilo Norata, </li></ul><span class="cited-by__entry__title">Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies, </span><span class="cited-by__entry__series-title">Expert Opinion on Therapeutic Targets, </span><span class="cited-by__entry__volume"><strong>29</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(137-157), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14728222.2025.2482545" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14728222.2025.2482545</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14728222.2025.2482545" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alesia Prillya Mauna, </li><li class="list-inline-item cited-by__entry__author">Joshua Eldad Frederich Lasanudin, </li></ul><span class="cited-by__entry__title">Efficacy of PCSK9 inhibitors on pediatric patients with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials, </span><span class="cited-by__entry__series-title">Cardiology Plus, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(61-68), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/CP9.0000000000000111" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/CP9.0000000000000111</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/CP9.0000000000000111" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lin Zhang, </li><li class="list-inline-item cited-by__entry__author">Bin Li, </li><li class="list-inline-item cited-by__entry__author">Wei Chen, </li><li class="list-inline-item cited-by__entry__author">Wei Li, </li><li class="list-inline-item cited-by__entry__author">Huayun Yang, </li><li class="list-inline-item cited-by__entry__author">Diguang Pan, </li></ul><span class="cited-by__entry__title">Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis, </span><span class="cited-by__entry__series-title">Reviews in Cardiovascular Medicine, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.31083/RCM25248" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.31083/RCM25248</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.31083/RCM25248" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yuhua Jiang, </li><li class="list-inline-item cited-by__entry__author">Yingying Wang, </li><li class="list-inline-item cited-by__entry__author">Sijia Ma, </li><li class="list-inline-item cited-by__entry__author">Linlin Qian, </li><li class="list-inline-item cited-by__entry__author">Yeteng Jing, </li><li class="list-inline-item cited-by__entry__author">Xi Chen, </li><li class="list-inline-item cited-by__entry__author">Jinsheng Yang, </li></ul><span class="cited-by__entry__title">Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis, </span><span class="cited-by__entry__series-title">Frontiers in Cardiovascular Medicine, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fcvm.2024.1415668" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fcvm.2024.1415668</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fcvm.2024.1415668" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amir Ajoolabady, </li><li class="list-inline-item cited-by__entry__author">Domenico Pratico, </li><li class="list-inline-item cited-by__entry__author">Mohsen Mazidi, </li><li class="list-inline-item cited-by__entry__author">Ian G. Davies, </li><li class="list-inline-item cited-by__entry__author">Gregory Y.H. Lip, </li><li class="list-inline-item cited-by__entry__author">Nabil Seidah, </li><li class="list-inline-item cited-by__entry__author">Peter Libby, </li><li class="list-inline-item cited-by__entry__author">Guido Kroemer, </li><li class="list-inline-item cited-by__entry__author">Jun Ren, </li></ul><span class="cited-by__entry__title">PCSK9 in metabolism and diseases, </span><span class="cited-by__entry__series-title">Metabolism, </span><span class="cited-by__entry__volume"><strong>163</strong>, </span><span class="cited-by__entry__page-range">(156064), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.metabol.2024.156064" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.metabol.2024.156064</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.metabol.2024.156064" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexis Llewellyn, </li><li class="list-inline-item cited-by__entry__author">Mark Simmonds, </li><li class="list-inline-item cited-by__entry__author">David Marshall, </li><li class="list-inline-item cited-by__entry__author">Melissa Harden, </li><li class="list-inline-item cited-by__entry__author">Beth Woods, </li><li class="list-inline-item cited-by__entry__author">Steve E. Humphries, </li><li class="list-inline-item cited-by__entry__author">Uma Ramaswami, </li><li class="list-inline-item cited-by__entry__author">Lorraine Priestley-Barnham, </li><li class="list-inline-item cited-by__entry__author">Mark Fisher, </li><li class="list-inline-item cited-by__entry__author">Laila J. Tata, </li><li class="list-inline-item cited-by__entry__author">Nadeem Qureshi, </li></ul><span class="cited-by__entry__title">Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials, </span><span class="cited-by__entry__series-title">Atherosclerosis, </span><span class="cited-by__entry__volume"><strong>401</strong>, </span><span class="cited-by__entry__page-range">(118598), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.atherosclerosis.2024.118598" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.atherosclerosis.2024.118598</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.atherosclerosis.2024.118598" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ibadete Bytyçi, </li><li class="list-inline-item cited-by__entry__author">Sefer Bytyqi, </li><li class="list-inline-item cited-by__entry__author">Joanna Lewek, </li><li class="list-inline-item cited-by__entry__author">Stanislaw Surma, </li><li class="list-inline-item cited-by__entry__author">Gani Bajraktari, </li><li class="list-inline-item cited-by__entry__author">Michael Henein, </li><li class="list-inline-item cited-by__entry__author">Amirhossein Sahebkar, </li><li class="list-inline-item cited-by__entry__author">Mutaz Al-Khnifsawi, </li><li class="list-inline-item cited-by__entry__author">Ioanna Gouni-Berthold, </li><li class="list-inline-item cited-by__entry__author">Ivan Pećin, </li><li class="list-inline-item cited-by__entry__author">Peter P Toth, </li><li class="list-inline-item cited-by__entry__author">Francesco Paneni, </li><li class="list-inline-item cited-by__entry__author">Niki Katsiki, </li><li class="list-inline-item cited-by__entry__author">Carlos Escobar, </li><li class="list-inline-item cited-by__entry__author">Carl J Lavie, </li><li class="list-inline-item cited-by__entry__author">Dan Gaita, </li><li class="list-inline-item cited-by__entry__author">Raul D Santos, </li><li class="list-inline-item cited-by__entry__author">Arrigo F G Cicero, </li><li class="list-inline-item cited-by__entry__author">Agata Bielecka-Dabrowa, </li><li class="list-inline-item cited-by__entry__author">Ali Ahmed, </li><li class="list-inline-item cited-by__entry__author">Maciej Banach, </li></ul><span class="cited-by__entry__title">Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis, </span><span class="cited-by__entry__series-title">European Heart Journal Open, </span><span class="cited-by__entry__volume"><strong>5</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/ehjopen/oeaf001" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/ehjopen/oeaf001</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/ehjopen/oeaf001" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Vera Bittner, </li></ul><span class="cited-by__entry__title">Treatment of heterozygous familial hypercholesterolaemia in children: is lower better?, </span><span class="cited-by__entry__series-title">European Journal of Preventive Cardiology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/eurjpc/zwaf008" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/eurjpc/zwaf008</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/eurjpc/zwaf008" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-14%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2019910%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019910" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2019910" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2019910.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f1.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/ed8a5984-4314-4602-b625-3ba9ad4f18bd/assets/images/large/nejmoa2019910_f1.jpg" height="1433" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Mean Percent Change in Low-Density Lipoprotein (LDL) Cholesterol Level.</div><div class="notes"><div role="doc-footnote">Shown are the unadjusted means and 95% confidence intervals for the percent change in LDL cholesterol level from baseline through the end of the trial at each scheduled visit. No imputation was used for missing values. Arrows indicate the subcutaneous administration of evolocumab (420 mg) or placebo at day 1, week 4, week 8, week 12, week 16, and week 20. 𝙸 bars indicate standard errors.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f2.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/b980666a-b138-49d9-96ab-06f52e5fc63d/assets/images/large/nejmoa2019910_f2.jpg" height="2029" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Efficacy End Points.</div><div class="notes"><div role="doc-footnote">Shown are forest plots of the between-group difference (evolocumab minus placebo) in the percent change in LDL cholesterol level from baseline to the mean of weeks 22 and 24 and to week 24 according to subgroup. A repeated-measures model was used for the analysis. To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. PCSK9 denotes proprotein convertase subtilisin–kexin type 9.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2019910/asset/5457cdc7-d52e-4ee1-9589-929fc324e7ed/assets/images/large/nejmoa2019910_t1.jpg" height="3438" width="1512" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Evolocumab<br>(N=104)</th><th class="txxr-borders">Placebo<br>(N=53)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">13.7±2.3</td><td class="xxxr-borders">13.7±2.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;14 yr</td><td class="xxxx-borders">48 (46)</td><td class="xxxr-borders">25 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥14 yr</td><td class="xxxx-borders shading">56 (54)</td><td class="xxxr-borders shading">28 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">61 (59)</td><td class="xxxr-borders">27 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">White race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">89 (86)</td><td class="xxxr-borders shading">44 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Weight — kg</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">55.3 (48.0–68.8)</td><td class="xxxr-borders shading">53.3 (42.4–61.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">10th percentile</td><td class="xxxx-borders">35.7</td><td class="xxxr-borders">35.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">90th percentile</td><td class="xxxx-borders shading">79.0</td><td class="xxxr-borders shading">80.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Height — cm</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">161.5 (152.0–168.0)</td><td class="xxxr-borders shading">158.5 (148.0–165.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">10th percentile</td><td class="xxxx-borders">143.8</td><td class="xxxr-borders">143.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">90th percentile</td><td class="xxxx-borders shading">173.0</td><td class="xxxr-borders shading">175.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">BMI-for-age category — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Underweight</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Normal</td><td class="xxxx-borders">62 (60)</td><td class="xxxr-borders">36 (68)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Overweight</td><td class="xxxx-borders shading">21 (20)</td><td class="xxxr-borders shading">8 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Obese</td><td class="xxxx-borders">19 (18)</td><td class="xxxr-borders">7 (13)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Geographic region — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">North America</td><td class="xxxx-borders">12 (12)</td><td class="xxxr-borders">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Europe</td><td class="xxxx-borders shading">68 (65)</td><td class="xxxr-borders shading">35 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Latin America</td><td class="xxxx-borders">18 (17)</td><td class="xxxr-borders">8 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asia–Pacific</td><td class="xxxx-borders shading">6 (6)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Cardiovascular risk factors — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Type 2 diabetes mellitus</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Family history of premature CHD</td><td class="xxxx-borders shading">31 (30)</td><td class="xxxr-borders shading">21 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Low HDL cholesterol</td><td class="xxxx-borders">40 (38)</td><td class="xxxr-borders">18 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Diagnosis of heterozygous FH — no. (%)</td><td class="xxxx-borders shading">104 (100)</td><td class="xxxr-borders shading">53 (100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Genetic</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>LDLR</i> mutation</td><td class="xxxx-borders shading">70 (67)</td><td class="xxxr-borders shading">30 (57)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left"><i>APOB</i> mutation</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>PCSK9</i> gain-of-function mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Clinical</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Simon Broome Register Group criteria</td><td class="xxxx-borders shading">9 (9)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Dutch Lipid Clinic Network criteria</td><td class="xxxx-borders">22 (21)</td><td class="xxxr-borders">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">MEDPED program criteria</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">4 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Statin use — no. (%)</td><td class="xxxx-borders">104 (100)</td><td class="xxxr-borders">52 (98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High intensity</td><td class="xxxx-borders shading">19 (18)</td><td class="xxxr-borders shading">7 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Moderate intensity</td><td class="xxxx-borders">63 (61)</td><td class="xxxr-borders">35 (66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Low intensity or unknown intensity</td><td class="xxxx-borders shading">22 (21)</td><td class="xxxr-borders shading">10 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Ezetimibe — no. (%)</td><td class="xxxx-borders">13 (12)</td><td class="xxxr-borders">8 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Lipid variables<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">LDL cholesterol — mg/dl</td><td class="xxxx-borders">185.0±45.0</td><td class="xxxr-borders">183.0±47.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">203.8±47.3</td><td class="xxxr-borders shading">200.2±48.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders">250.7±47.0</td><td class="xxxr-borders">247.3±49.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">46.8±12.0</td><td class="xxxr-borders shading">47.2±11.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median triglycerides (IQR) — mg/dl</td><td class="xxxx-borders">86.8 (63.8–117.0)</td><td class="xxxr-borders">78.0 (62.5–101.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders shading">50.5 (18.0–126.5)</td><td class="xxxr-borders shading">34.0 (21.0–147.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">PCSK9 — ng/ml</td><td class="xbxx-borders">277.2±92.1</td><td class="xbxr-borders">294.2±101.3</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Patients were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of either evolocumab (420 mg) or placebo for 24 weeks. Data from all 157 patients were used for analysis. To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. Percentages may not total 100 because of rounding. CHD denotes coronary heart disease, FH familial hypercholesterolemia, HDL high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, and MEDPED Make Early Diagnosis to Prevent Early Deaths.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><div class="label">‡</div></a><div id="core-t1fn3" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg">The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. BMI-for-age categories are based on expert committee recommendations<sup></sup></a><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15 r16" id="core-body-ref-r16" href-manipulated="true" data-to-manipulate="false">14-16</a> (underweight, &lt;5th percentile; normal, ≥5th percentile to &lt;85th percentile; overweight, ≥85th percentile to &lt;95th percentile; and obese, ≥95th percentile).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Shown are hypertension and diabetes diagnoses as provided by the investigators and entered in the trial clinical research form; no definition of hypertension was specifically used in the trial. A low HDL cholesterol level was defined as less than 40 mg per deciliter (1.0 mmol per liter) in patients 10 years of age to younger than 16 years of age, less than 40 mg per deciliter in male patients 16 years of age or older, and less than 50 mg per deciliter (1.3 mmol per liter) in female patients 16 years of age or older.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">For lipoprotein(a), 2 patients in the placebo group had missing values; for proprotein convertase subtilisin–kexin type 9 (PCSK9), 7 patients in the evolocumab group and 1 patient in the placebo group had missing values.</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2019910/asset/505b892e-2303-4944-807c-3f5996be8990/assets/images/large/nejmoa2019910_t2.jpg" height="1338" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Evolocumab<br>(N=104)<a href="#core-t2fn1" role="doc-noteref">*</a></th><th class="txxx-borders">Placebo<br>(N=53)<a href="#core-t2fn1" role="doc-noteref">*</a></th><th class="txxx-borders">Difference<br>(95% CI)<a href="#core-t2fn1" role="doc-noteref">*</a><a href="#core-t2fn2" role="doc-noteref">†</a></th><th class="txxr-borders">Adjusted P Value</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in LDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−44.5 (−48.8 to −40.3)</td><td class="xxxx-borders shading">−6.2 (−12.3 to −0.2)</td><td class="xxxx-borders shading">−38.3 (−45.5 to −31.1)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in LDL cholesterol from baseline to wk 22 and 24 (95% CI)</td><td class="xxxx-borders">−48.0 (−51.7 to −44.2)</td><td class="xxxx-borders">−5.9 (−11.1 to −0.6)</td><td class="xxxx-borders">−42.1 (−48.3 to −35.8)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Absolute change in LDL cholesterol from baseline to wk 24 (95% CI) — mg/dl</td><td class="xxxx-borders shading">−77.5 (−86.1 to −68.9)</td><td class="xxxx-borders shading">−9.0 (−21.1 to 3.2)</td><td class="xxxx-borders shading">−68.6 (−83.1 to −54.0)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in non-HDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders">−41.2 (−45.2 to −37.2)</td><td class="xxxx-borders">−6.1 (−11.8 to −0.5)</td><td class="xxxx-borders">−35.0 (−41.8 to −28.3)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in apolipoprotein B from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−34.9 (−38.6 to −31.1)</td><td class="xxxx-borders shading">−2.4 (−7.7 to 3.0)</td><td class="xxxx-borders shading">−32.5 (−38.8 to −26.1)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in ratio of total cholesterol to HDL cholesterol from baseline to wk 24 (95% CI)</td><td class="xxxx-borders">−35.0 (−38.6 to −31.4)</td><td class="xxxx-borders">−4.7 (−9.8 to 0.5)</td><td class="xxxx-borders">−30.3 (−36.4 to −24.2)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Percent change in ratio of apolipoprotein B to apolipoprotein A1 from baseline to wk 24 (95% CI)</td><td class="xxxx-borders shading">−37.0 (−40.9 to −33.2)</td><td class="xxxx-borders shading">−0.6 (−6.2 to 4.9)</td><td class="xxxx-borders shading">−36.4 (−43.0 to −29.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Percent change in lipoprotein(a) from baseline to wk 24 (95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">−7.4 (−20.1 to 5.3)</td><td class="xxxx-borders">1.7 (−17.0 to 20.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Percent change in lipoprotein(a) from baseline to wk 22 and 24 (95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders shading">−10.3 (−18.7 to −1.9)</td><td class="xbxx-borders shading">1.6 (−10.4 to 13.7)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Shown are least-squares means from the repeated-measures model, which includes trial group, stratification factor of age at baseline and LDL cholesterol level at the time of screening (from the interactive voice-response system), scheduled visit, and the interaction of treatment with scheduled visit as covariates.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The difference is the value in the evolocumab group minus the value in the placebo group. Differences are expressed as percentage points, except for the absolute change in LDL cholesterol level (expressed as milligrams per deciliter).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Lipoprotein(a) was a tertiary end point.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Secondary Efficacy End Points.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2019910/asset/ff9757b9-0ca0-4ceb-8a09-aecf0b20a2fc/assets/images/large/nejmoa2019910_t3.jpg" height="1711" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Evolocumab<br>(N=104)</th><th class="txxr-borders">Placebo<br>(N=53)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>no. of patients (%)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">64 (62)</td><td class="xxxr-borders shading">34 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of regimen</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Serious</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonserious</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Most common adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">12 (12)</td><td class="xxxr-borders shading">6 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">11 (11)</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Oropharyngeal pain</td><td class="xxxx-borders shading">7 (7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Influenza</td><td class="xxxx-borders">6 (6)</td><td class="xxxr-borders">2 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">6 (6)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">5 (5)</td><td class="xxxr-borders">4 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">3 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Constipation</td><td class="xxxx-borders">3 (3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Influenza-like illness</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Injection-site reaction</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Laboratory results at wk 24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Aminotransferase level &gt;3× ULN</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Creatine kinase level &gt;5× ULN</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Development of anti-evolocumab antibodies<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xbxx-borders">0</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">ULN denotes the upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Anti-evolocumab antibody assessment by means of an electrochemiluminescence-based immunoassay was performed at day 1 (randomization), week 12, and week 24 (end of the trial). None of the patients tested positive at any time point.</div></div></div></figcaption></a><figcaption><div class="caption">Safety Data.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2019910_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2019910</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. <em>Nat Rev Dis Primers</em> 2017;3:17093-17093.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrdp.2017.93" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29219151/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417650300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia.&amp;publication_year=2017&amp;journal=Nat+Rev+Dis+Primers&amp;pages=17093-17093&amp;doi=10.1038%2Fnrdp.2017.93&amp;pmid=29219151" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] LDL receptor adaptor protein 1 (LDLRAP1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] more modest than those for adults, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. <em>Circulation</em> 2020;141:1742-1759.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32468833/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538162700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+familial+hypercholesterolemia+among+the+general+population+and+patients+with+atherosclerotic+cardiovascular+disease%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=Circulation&amp;pages=1742-1759&amp;doi=10.1161%2FCIRCULATIONAHA.119.044795&amp;pmid=32468833" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in <i>PCSK9</i>, low LDL, and protection against coronary heart disease. <em>N Engl J Med</em> 2006;354:1264-1272.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa054013&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16554528/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236164200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Sequence+variations+in+PCSK9%2C+low+LDL%2C+and+protection+against+coronary+heart+disease.&amp;publication_year=2006&amp;journal=N+Engl+J+Med&amp;pages=1264-1272&amp;doi=10.1056%2FNEJMoa054013&amp;pmid=16554528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <em>Eur Heart J</em> 2015;36:2425-2437.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehv157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26009596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362044000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia+in+children+and+adolescents%3A+gaining+decades+of+life+by+optimizing+detection+and+treatment.&amp;publication_year=2015&amp;journal=Eur+Heart+J&amp;pages=2425-2437&amp;doi=10.1093%2Feurheartj%2Fehv157&amp;pmid=26009596" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterozygous familial hypercholesterolemia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <em>Circulation</em> 2019;139(25):e1082-e1143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471794100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2018+AHA%2FACC%2FAACVPR%2FAAPA%2FABC%2FACPM%2FADA%2FAGS%2FAPhA%2FASPC%2FNLA%2FPCNA+guideline+on+the+management+of+blood+cholesterol%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=e1082-e1143&amp;pmid=30586774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] heterozygous familial hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with familial hypercholesterolemia. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <em>Eur Heart J</em> 2020;41:111-188.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605984300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias%3A+lipid+modification+to+reduce+cardiovascular+risk.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;pages=111-188&amp;doi=10.1093%2Feurheartj%2Fehz455&amp;pmid=31504418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Ramaswami U, Futema M, Bogsrud MP, et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <em>Atherosclerosis</em> 2020;292:178-187.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2019.11.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31809987/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503400300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+characteristics+at+diagnosis+and+treatment+of+children+with+heterozygous+familial+hypercholesterolaemia+%28FH%29+from+eight+European+countries.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=178-187&amp;doi=10.1016%2Fj.atherosclerosis.2019.11.012&amp;pmid=31809987" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with familial hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] appropriate in all the patients studied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. <em>J Clin Pharmacol</em> 2017;57:7-32.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.766" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27195910/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392014300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+monoclonal+antibodies%3A+modern+management+of+hypercholesterolemia.&amp;publication_year=2017&amp;journal=J+Clin+Pharmacol&amp;pages=7-32&amp;doi=10.1002%2Fjcph.766&amp;pmid=27195910" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <em>N Engl J Med</em> 2017;376:1713-1722.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1615664&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28304224/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400442300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolocumab+and+clinical+outcomes+in+patients+with+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1713-1722&amp;doi=10.1056%2FNEJMoa1615664&amp;pmid=28304224" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. <em>J Am Coll Cardiol</em> 2020;75:565-574.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.12.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32057369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512903000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+evolocumab+in+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=565-574&amp;doi=10.1016%2Fj.jacc.2019.12.020&amp;pmid=32057369" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with Genetic LDL Disorders (TAUSSIG) </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2015;385:331-340.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61399-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25282519/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348509000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+evolocumab+%28AMG+145%29+in+heterozygous+familial+hypercholesterolaemia+%28RUTHERFORD-2%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=331-340&amp;doi=10.1016%2FS0140-6736%2814%2961399-4&amp;pmid=25282519" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. <em>J Am Coll Cardiol</em> 2019;74:2132-2146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.08.1024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31648705/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491235900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+efficacy+and+safety+of+evolocumab+in+patients+with+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Am+Coll+Cardiol&amp;pages=2132-2146&amp;doi=10.1016%2Fj.jacc.2019.08.1024&amp;pmid=31648705" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Langslet G, Gidding SS, et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. <em>J Clin Lipidol</em> 2018;12:1199-1207.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacl.2018.05.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30318065/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000447815400020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+tolerability+of+evolocumab+in+pediatric+patients+with+heterozygous+familial+hypercholesterolemia%3A+rationale+and+design+of+the+HAUSER-RCT+study.&amp;publication_year=2018&amp;journal=J+Clin+Lipidol&amp;pages=1199-1207&amp;doi=10.1016%2Fj.jacl.2018.05.007&amp;pmid=30318065" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Amgen sponsored and designed the trial </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] criteria was reported previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] thickness for atherosclerosis progression, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Barlow SE, Expert Committee. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. <em>Pediatrics</em> 2007;120:Suppl 4:S164-S192.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1542/peds.2007-2329C" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18055651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253378300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Expert+Committee+recommendations+regarding+the+prevention%2C+assessment%2C+and+treatment+of+child+and+adolescent+overweight+and+obesity%3A+summary+report.&amp;publication_year=2007&amp;journal=Pediatrics&amp;pages=S164-S192&amp;doi=10.1542%2Fpeds.2007-2329C&amp;pmid=18055651" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Cote AT, Harris KC, Panagiotopoulos C, Sandor GG, Devlin AM. Childhood obesity and cardiovascular dysfunction. <em>J Am Coll Cardiol</em> 2013;62:1309-1319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2013.07.042" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23954339/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325005000002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Childhood+obesity+and+cardiovascular+dysfunction.&amp;publication_year=2013&amp;journal=J+Am+Coll+Cardiol&amp;pages=1309-1319&amp;doi=10.1016%2Fj.jacc.2013.07.042&amp;pmid=23954339" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Whitlock EP, Williams SB, Gold R, Smith PR, Shipman SA. Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. <em>Pediatrics</em> 2005;116(1):e125-e144.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1542/peds.2005-0242" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15995013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230207500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Screening+and+interventions+for+childhood+overweight%3A+a+summary+of+evidence+for+the+US+Preventive+Services+Task+Force.&amp;publication_year=2005&amp;journal=Pediatrics&amp;pages=e125-e144&amp;doi=10.1542%2Fpeds.2005-0242&amp;pmid=15995013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. <em>N Engl J Med</em> 2019;381:1547-1556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1816454&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31618540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491085100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=20-Year+follow-up+of+statins+in+children+with+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=1547-1556&amp;doi=10.1056%2FNEJMoa1816454&amp;pmid=31618540" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. <em>JAMA</em> 2019;322:1780-1788.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.16585" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31714986/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000498675500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+bempedoic+acid+vs+placebo+added+to+maximally+tolerated+statins+on+low-density+lipoprotein+cholesterol+in+patients+at+high+risk+for+cardiovascular+disease%3A+the+CLEAR+Wisdom+randomized+clinical+trial.&amp;publication_year=2019&amp;journal=JAMA&amp;pages=1780-1788&amp;doi=10.1001%2Fjama.2019.16585&amp;pmid=31714986" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Durst R, Lepor N, et al. Usefulness of gemcabene in homozygous familial hypercholesterolemia (from COBALT-1). <em>Am J Cardiol</em> 2019;124:1876-1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjcard.2019.09.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31685212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503909900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Usefulness+of+gemcabene+in+homozygous+familial+hypercholesterolemia+%28from+COBALT-1%29.&amp;publication_year=2019&amp;journal=Am+J+Cardiol&amp;pages=1876-1880&amp;doi=10.1016%2Fj.amjcard.2019.09.010&amp;pmid=31685212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2020;382:1520-1530.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMoa1913805&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32197277/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000527733300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inclisiran+for+the+treatment+of+heterozygous+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1520-1530&amp;doi=10.1056%2FNEJMoa1913805&amp;pmid=32197277" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2017;377:296-297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2019910&amp;key=10.1056%2FNEJMc1705994&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28723334/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+inhibition+in+homozygous+familial+hypercholesterolemia.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=296-297&amp;doi=10.1056%2FNEJMc1705994&amp;pmid=28723334" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2015;385:341-350.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61374-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25282520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348509000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+PCSK9+with+evolocumab+in+homozygous+familial+hypercholesterolaemia+%28TESLA+Part+B%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=341-350&amp;doi=10.1016%2FS0140-6736%2814%2961374-X&amp;pmid=25282520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Daniels S, Caprio S, Chaudhari U, et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. <em>J Clin Lipidol</em> 2020;14:322-330.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacl.2020.03.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32331936/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000540548500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+with+alirocumab+in+pediatric+patients+with+heterozygous+familial+hypercholesterolemia%3A+the+ODYSSEY+KIDS+study.&amp;publication_year=2020&amp;journal=J+Clin+Lipidol&amp;pages=322-330.e5&amp;doi=10.1016%2Fj.jacl.2020.03.001&amp;pmid=32331936" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 30, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2027599" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Evolocumab in Children with Heterozygous Familial Hypercholesterolemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.D. de Ferranti</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 06, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2032399" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Staten Island, New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/726362/gastroenterology-inflammatory-bowel-disease-staten-island-university-hospital/?query=fjwp&amp;rid=3059">Gastroenterology - Inflammatory Bowel Disease, Staten Island University Hospital</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/864598/neuroradiologist/?query=fjwp&amp;rid=3059">Neuroradiologist</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/392535/obgyn-generalists-laborists-safety-officers/?query=fjwp&amp;rid=3059">OBGYN Generalists/Laborists/Safety Officers</a></div></div><div class="nejm-widget_item"><div><span> Vero Beach, Florida</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886369/concierge-medicine-physician-cleveland-clinic-florida-indian-river-hospital-/?query=fjwf&amp;rid=2201">Concierge Medicine Physician, Cleveland Clinic Florida (Indian River Hospital)</a></div></div><div class="nejm-widget_item"><div><span> San Francisco, California</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889322/physician-orthopedic-surgery-san-francisco-ca-/?query=fjwf&amp;rid=845672">Physician, Orthopedic Surgery (San Francisco, CA)</a></div></div><div class="nejm-widget_item"><div><span> Vernon, Illinois</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881000/exceptional-opportunity-for-endocrinologist-ready-to-make-a-lasting-impact-step-up-and-make-your-m/?query=fjwf&amp;rid=196467">Exceptional Opportunity for Endocrinologist! Ready to make a Lasting Impact? Step Up and Make Your M</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2019910&amp;pubId=41289149&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d64be1069800ae-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d64be1069800ae-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d64be1069800ae-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$872926439$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$872926439$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$872926439$--></div></div><div class="mlt-body"><!--?lit$872926439$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$872926439$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$872926439$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$872926439$-->Dec 24, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400112?query=recirc_Semantic" target="_self">Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab</a></div><div class="mlt-article-authors"><!--?lit$872926439$-->A. Zimerman and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/editorial?query=recirc_Semantic" target="_self"><!--?lit$872926439$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$872926439$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$872926439$-->Dec 24, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDe2400391?query=recirc_Semantic" target="_self">Low LDL, High Reassurance? Evolocumab’s Long-Term Cognitive Safety Profile</a></div><div class="mlt-article-authors"><!--?lit$872926439$-->K. Zorcic and S.S. Gill</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$872926439$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$872926439$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$872926439$-->Mar 27, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2413726?query=recirc_Semantic" target="_self">Severe HDL Cholesterol Reduction with Bempedoic Acid and Fenofibrate</a></div><div class="mlt-article-authors"><!--?lit$872926439$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$872926439$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$872926439$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$872926439$-->May 07, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2415820?query=recirc_Semantic" target="_self">Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk</a></div><div class="mlt-article-authors"><!--?lit$872926439$-->S.J. Nicholls and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$872926439$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$872926439$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$872926439$-->Dec 05, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405182?query=recirc_Semantic" target="_self">Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women</a></div><div class="mlt-article-authors"><!--?lit$872926439$-->P.M. Ridker and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2019910?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2019910" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2019910.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2019910"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2019422" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Early Rhythm-Control Therapy in Patients with Atrial Fibrillation</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1917346" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f1.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/ed8a5984-4314-4602-b625-3ba9ad4f18bd/assets/images/large/nejmoa2019910_f1.jpg" height="1433" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Mean Percent Change in Low-Density Lipoprotein (LDL) Cholesterol Level.</div><div class="notes"><div role="doc-footnote">Shown are the unadjusted means and 95% confidence intervals for the percent change in LDL cholesterol level from baseline through the end of the trial at each scheduled visit. No imputation was used for missing values. Arrows indicate the subcutaneous administration of evolocumab (420 mg) or placebo at day 1, week 4, week 8, week 12, week 16, and week 20. 𝙸 bars indicate standard errors.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2019910_f2.jpg"><img src="/cms/10.1056/NEJMoa2019910/asset/b980666a-b138-49d9-96ab-06f52e5fc63d/assets/images/large/nejmoa2019910_f2.jpg" height="2029" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Subgroup Analysis of Efficacy End Points.</div><div class="notes"><div role="doc-footnote">Shown are forest plots of the between-group difference (evolocumab minus placebo) in the percent change in LDL cholesterol level from baseline to the mean of weeks 22 and 24 and to week 24 according to subgroup. A repeated-measures model was used for the analysis. To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. PCSK9 denotes proprotein convertase subtilisin–kexin type 9.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Efficacy End Points.</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Safety Data.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/14" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 14</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2019422" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Early Rhythm-Control Therapy in Patients with Atrial Fibrillation</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Kirchhof and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1917338" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">HPV Vaccination and the Risk of Invasive Cervical Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Lei and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1917346" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.S. Herbst and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2019910%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2019910&amp;pubId=41289149&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2019910%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2019910&amp;pubId=41289149&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06151487794553012" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d64be1069800ae-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d64be1069800ae-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d64be1069800ae-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d64be1069800ae-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d64be1069800ae-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d64be1069800ae-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d64be1069800ae-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d64be1069800ae-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d64be1069800ae-SJC"></script>
            
            
            
        
    




<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d64be1069800ae-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d64be0eeff00ae',t:'MTc0OTUzMTUzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d64be0eeff00ae&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2019910?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><zca-dtzuztpzhzcr></zca-dtzuztpzhzcr><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-transactionid="50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" id="captureIFrame_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" target="captureIFrame_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="capture_screen"><input id="capture_signIn_js_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="js_version"><input id="capture_signIn_transactionId_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" type="hidden" class="capture_transactionId_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="capture_transactionId"><input id="capture_signIn_form_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="form"><input id="capture_signIn_flow_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="flow"><input id="capture_signIn_client_id_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="client_id"><input id="capture_signIn_redirect_uri_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="redirect_uri"><input id="capture_signIn_response_type_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="response_type"><input id="capture_signIn_flow_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="flow_version"><input id="capture_signIn_settings_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="settings_version"><input id="capture_signIn_locale_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="locale"><input id="capture_signIn_recaptcha_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_50mkl74utqkijb7kjy601owd1vg14npp0xaxsa2j" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>